Provided by Tiger Trade Technology Pte. Ltd.

3SBIO

17.580
-0.080-0.45%
Volume:11.64M
Turnover:207.25M
Market Cap:44.48B
PE:4.39
High:18.100
Open:17.660
Low:17.440
Close:17.660
52wk High:36.264
52wk Low:14.594
Shares:2.53B
HK Float Shares:2.53B
Volume Ratio:0.64
T/O Rate:0.46%
Dividend:0.26
Dividend Rate:1.49%
EPS(LYR):4.001
ROE:35.88%
ROA:22.68%
PB:1.39
PE(LYR):4.39
PS:2.13

Loading ...

CICC Keeps Outperform Rating on 3SBIO, Trims Target Price to HK$30.00

Stock News
·
Aug 24

3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline

Simply Wall St.
·
Aug 21

3SBio H1 FY26 Net Profit Rises 26.5% to RMB 1.44 Billion; Revenue Increases 3.9% to RMB 4.53 Billion

Reuters
·
Aug 21

Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

Dow Jones
·
Aug 21

Morning Market Pulse: Hang Seng Index Climbs 0.72% in Early Session, Lithium Miners Lead Gains

Stock News
·
Aug 21

Hong Kong Stock Alert: 3SBIO Surges Over 7% on Strong First-Half Adjusted Operating Profit Growth

Stock News
·
Aug 21

Movement Alert|3SBIO Rises 5.58% in Regular Trading, H1 Adjusted Profit Up 26.5% and New Drug Approval Boost Sentiment

Market Focus
·
Aug 21

Press Release: Sunshine Guojian Releases 2026 Interim Report:

Dow Jones
·
Aug 21

China's 3SBio H1 Net Profit Falls on Higher Expenses

Reuters
·
Aug 20

3SBio H1 Revenue RMB 4,526 Million

THOMSON REUTERS
·
Aug 20

China National Medical Products Administration: Approves 3S Guojian's Nonsteroidal Anti-Inflammatory Drug

THOMSON REUTERS
·
Aug 20

Movement Alert|3SBIO Rises 5.15% in Regular Trading, Interim Results Review and Biotech Sector Strength Fuel Gains

Market Focus
·
Aug 20

Earning Preview: 3SBIO Q2 revenue expected to increase, institutional views are mixed-to-cautious

Earnings Agent
·
Aug 13

Movement Alert|3SBIO Rises 5.18% in Regular Trading, Interim Results Review Approaching with Broker Top Pick Catalyst

Market Focus
·
Aug 10

GRAND PHARMA (00512) Secures FDA Fast Track for Its Independently Developed Global First-in-Class RDC Diagnostic for Solid Tumors

Stock News
·
Aug 09

3SBio Schedules 20 August 2026 Board Meeting to Approve H1 2026 Results and Consider Interim Dividend

Bulletin Express
·
Aug 07

3SBio Schedules Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 07

3SBio Issues Additional 0.16 Million Shares After Option Exercise; Total Outstanding Reaches 2.53 Billion

Bulletin Express
·
Aug 04

Movement Alert|3SBio Rises 5.51% in Regular Trading, Biotech Sector Rally Combined with Oversold Rebound

Market Focus
·
Jul 20

Movement Alert|3SBio Falls 5.64% in Regular Trading, Institutional Selling Compounds Biotech Sector Pullback

Market Focus
·
Jul 17